Sophie Bakri

About Sophie Bakri

Sophie Bakri

Bakri considers her work in describing the pharmacokinetics of intravitreal therapies as one of her biggest achievements so far, and has hopes that her current work on new pharmacotherapies for retinal vascular diseases, such as AMD and diabetic retinopathy, will result in more convenient and effective ways to treat patients. She believes that if sustained drug delivery of anti-VEGF therapy becomes a reality, it could be a game-changer.

With over 100 peer-reviewed papers and 17 book chapters on retinal disease, she is also editor-in-chief of the book “Mayo Clinic on Vision and Eye Health”, and serves on the Editorial Board of the American Journal of Ophthalmology, Retina, Seminars in Ophthalmology and Clinical and Surgical Ophthalmology.

She is a principal investigator in several multicenter clinical trials on novel drugs for retinal disease, and has received an Achievement Award from the AAO, and an Honor Award from the ASRS. Her advice: “There is no substitute for hard work. And listen carefully to your patients – they will give you the answers as to what the unmet needs are in ophthalmology.”